• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form SC 13D/A filed by Tango Therapeutics Inc.

    10/15/24 7:25:19 PM ET
    $TNGX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $TNGX alert in real time by email
    SC 13D/A 1 ff3993768_13da4-tango.htm



    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549
    SCHEDULE 13D
    (RULE 13D - 101)
    INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO 13d-1(a) AND
    AMENDMENTS THERETO FILED PURSUANT TO 13d-2(a)
    (Amendment No. 4)*
    Tango Therapeutics, Inc.
    (Name of Issuer)
    Common Stock, $0.001 par value per share
    (Title of Class of Securities)

    87583X109
    (CUSIP Number)


    Josh La Grange
    Fried, Frank, Harris, Shriver & Jacobson LLP
    801 17th Street, NW, Washington, DC 20006
    202-639-7497
     (Name, Address and Telephone Number of Person
    Authorized to Receive Notices and Communications)


    October 10, 2024
     (Date of Event which Requires Filing of this Statement)

    If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box ☐.
    Note: Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See §240.13d-7 for other parties to whom copies are to be sent.
    * The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.
    The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).



    CUSIP No. 87583X109

    1
    NAMES OF REPORTING PERSONS
     
     
     
    Boxer Asset Management Inc.
     
     
     
     
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
    (a)
    ☐
     
    (b)
    ☐
     
     
    3
    SEC USE ONLY
     
     
     
     
     
     
     
    4
    SOURCE OF FUNDS (SEE INSTRUCTIONS)
     
     
     
    N/A
     
     
     
     
    5
    CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(D) OR 2(E)
     
    ☐
     
     
     
     
     
    6
    CITIZENSHIP OR PLACE OF ORGANIZATION
     
     
     
    Bahamas
     
     
     
     
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH
    7
    SOLE VOTING POWER
     
     
     0
     
     
     
     
    8
    SHARED VOTING POWER
     
     
     0
     
     
     
     
    9
    SOLE DISPOSITIVE POWER
     
     
     0
     
     
     
     
    10
    SHARED DISPOSITIVE POWER
     
     
     0
     
     
     
     
    11
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
     
     0
     
     
     
     
    12
    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)
     
    ☐
     
     
     
     
     
    13
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
     
     
     0%
     
     
     
     
    14
    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
     
     
     CO
     
     
     
     





    CUSIP No. 87583X109

    1
    NAMES OF REPORTING PERSONS
     
     
     
    Braslyn Ltd.
     
     
     
     
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
    (a)
    ☐
     
    (b)
    ☐
     
     
    3
    SEC USE ONLY
     
     
     
     
     
     
     
    4
    SOURCE OF FUNDS (SEE INSTRUCTIONS)
     
     
     
    N/A
     
     
     
     
    5
    CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(D) OR 2(E)
     
    ☐
     
     
     
     
     
    6
    CITIZENSHIP OR PLACE OF ORGANIZATION
     
     
     
    Bahamas
     
     
     
     
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH
    7
    SOLE VOTING POWER
     
     
     0
     
     
     
     
    8
    SHARED VOTING POWER
     
     
     
    26,961
     
     
     
     
    9
    SOLE DISPOSITIVE POWER
     
     
    0
     
     
     
     
    10
    SHARED DISPOSITIVE POWER
     
     
     
    26,961
     
     
     
     
    11
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
     
    26,961
     
     
     
     
    12
    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)
     
    ☐
     
     
     
     
     
    13
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
     
     
    Less than  0.1%
     
     
     
     
    14
    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
     
     
     OO
     
     
     
     





    CUSIP No. 87583X109

    1
    NAMES OF REPORTING PERSONS
     
     
     
    Joe Lewis
     
     
     
     
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
    (a)
    ☐
     
    (b)
    ☐
     
     
    3
    SEC USE ONLY
     
     
     
     
     
     
     
    4
    SOURCE OF FUNDS (SEE INSTRUCTIONS)
     
     
     
    N/A
     
     
     
     
    5
    CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(D) OR 2(E)
     
    ☐
     
     
     
     
     
    6
    CITIZENSHIP OR PLACE OF ORGANIZATION
     
     
     
    United Kingdom
     
     
     
     
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH
    7
    SOLE VOTING POWER
     
     
     0
     
     
     
     
    8
    SHARED VOTING POWER
     
     
     
    26,961
     
     
     
     
    9
    SOLE DISPOSITIVE POWER
     
     
     0
     
     
     
     
    10
    SHARED DISPOSITIVE POWER
     
     
     
    26,961
     
     
     
     
    11
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
     
     
    26,961
     
     
     
     
    12
    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)
     
    ☐
     
     
     
     
     
    13
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
     
     
     
    Less than 0.1%
     
     
     
     
    14
    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
     
     
     IN
     
     
     
     






    With respect to Joe Lewis, Braslyn Ltd. (“Braslyn”) and Boxer Asset Management Inc. (“Boxer Management,” and together with Mr. Lewis and Braslyn, the “Reporting Persons”), this amendment (this “Amendment No. 4”) further amends and supplements the statement on Schedule 13D filed on August 20, 2021 (the “Original Filing”) by BCTG Holdings, LLC (“BCTG Holdings”), Boxer Capital, LLC (“Boxer Capital”), Boxer Management, MVA Investors, LLC (“MVA Investors”), Aaron I. Davis and Mr. Lewis with respect to the Common Stock, par value $0.001 (the “Common Stock”) of Tango Therapeutics, Inc. (the “Issuer”), as previously amended and filed on January 4, 2022 (“Amendment No. 1”), August 16, 2023 (“Amendment No. 2”) and October 18, 2023 (“Amendment No. 3”). Amendment No. 1 was an original filing for Braslyn. On October 10, 2024, Boxer Capital entered into an investment management agreement (the “IMA”) with Boxer Capital Management LLC (“BCM”), a registered investment advisor controlled by Mr. Davis. Pursuant to the IMA, Boxer Capital has delegated exclusive voting and investment power over its investment portfolio to BCM. Consequently, BCM has acquired beneficial ownership of the securities held in Boxer Capital’s investment portfolio and, without reflecting any change in its economic interest in such securities, Boxer Capital has thereby ceased to beneficially own the securities held in its investment portfolio, including shares of Common Stock. Consequently, each of Boxer Management and Mr. Lewis has ceased to beneficially own the securities held in Boxer Capital’s investment portfolio. Capitalized terms used herein but not defined herein shall have the respective meanings defined in the Original Filing, as previously amended. The Original Filing, as previously amended, is further amended hereby only as specifically set forth herein, provided that with respect to any Item amended herein, if such Item is incorporated by reference into any other Item in the Original Filing, as previously amended, such incorporation by reference is also amended hereby. The Reporting Persons report herein that they have ceased to beneficially own more than 5% of the outstanding shares of Common Stock. On or about the day of this filing, Boxer Capital, MVA Investors, BCTG Holdings and Mr. Davis are independently amending the Original Filing with respect to themselves, which filing is being joined by BCM; see that filing for any required information pertaining to any of them.

    Item 2.
    Identity and Background.

    Item 2 is hereby amended and restated to read as follows:
    This Schedule 13D is jointly filed by Boxer Management, Braslyn and Mr. Lewis.
    Boxer Management, a Bahamian international business company, is the managing member and majority owner of Boxer Capital, a limited liability company organized under the laws of Delaware. Braslyn is a corporation organized under the laws of the Bahamas. Mr. Lewis is the sole indirect owner of and controls Boxer Management and Braslyn. Each of Boxer Management and Braslyn are primarily engaged in the business of investing in securities. Mr. Lewis is a citizen of the United Kingdom and his present principal occupation or employment is engaging in business as a private investor including through the investments of Boxer Capital and Braslyn.
    The address of each of Boxer Management, Braslyn and Mr. Lewis for purposes of this filing is: Albany Financial Center, Suite 207, Lewis Drive, N7776, New Providence, Bahamas.
    Set forth on Schedule A, and incorporated herein by reference, is the (a) name, (b) residence or business address, (c) present principal occupation or employment and (d) citizenship, of each executive officer and director of each of Boxer Management and Braslyn, and (e) name of any corporation or other organization in which such occupation or employment is conducted, together with the principal business and address of any such corporation or organization other than Boxer Management and Braslyn.
    Except as set forth on Schedule B to this Schedule 13D, none of the Reporting Persons nor any of the individuals identified on Schedule A to this Schedule 13D has, during the past five years, (a) been convicted in a criminal proceeding (excluding traffic violations or similar misdemeanors), or (b) been a party to a civil proceeding of a judicial or administrative body of competent jurisdiction and as a result of such proceeding was or is subject to a judgment, decree or final order enjoining future violations of, or prohibiting, or mandating activities subject to, federal or state securities laws or a finding of any violation with respect to such laws.

    Item 3.
    Source and Amount of Funds or Other Consideration.

    Item 3 is hereby amended by the addition of the following:

    The disclosure set forth below in Item 4 is hereby incorporated herein.

    Item 4.
    Purpose of Transaction.

    Item 4 is hereby amended by the addition of the following:

    On October 10, 2024, Boxer Management, Boxer Capital and BCM entered into the IMA, pursuant to which Boxer Capital has delegated exclusive voting and investment power over its investment portfolio to BCM. Consequently, BCM has acquired beneficial ownership of the shares of Common Stock held by Boxer Capital and, without reflecting any change in its economic interest in such securities, Boxer Capital has thereby ceased to beneficially own the securities held in its investment portfolio, including shares of Common Stock. Consequently, each of Boxer Management and Mr. Lewis has ceased to beneficially own the securities held in Boxer Capital’s investment portfolio.





    Item 5.
    Interest in Securities of the Issuer.

    Item 5 is hereby amended and restated to read as follows:
     
    All percentages are based on 107,144,465 shares of the Issuer’s Common Stock outstanding as of August 1, 2024 as set forth in the Issuer’s 10-Q filed with the Securities and Exchange Commission on August 7, 2024.
    (a) The Reporting Persons may be deemed to beneficially own, in the aggregate, 26,961 shares of Common Stock, representing less than 0.1% of the outstanding shares of Common Stock.
    (b) With respect to any rights or powers to vote, or to direct the vote of, or to dispose of, or to direct the disposition of, the Common Stock owned by the Reporting Persons:

     
    (i)
    Sole power to vote or to direct the vote:

       
    None of the Reporting Persons has the sole power to vote or to direct the vote of shares of the Common Stock.

     
    (ii)
    Shared power to vote or to direct the vote:

       
    Braslyn and Mr. Lewis have shared power to vote or to direct the vote of 26,961 shares of Common Stock.

     
    (iii)
    Sole power to dispose or to direct the disposition of:

       
    None of the Reporting Persons has the sole power to dispose or direct the disposition of shares of the Common Stock.

     
    (iv)
    Shared power to dispose or to direct the disposition of:

       
    Braslyn and Mr. Lewis have shared power to dispose or direct the disposition of 26,961 shares of Common Stock.
    (c) Other than as described herein in Item 4 or transactions previously reported on Form 4, the Reporting Persons have not engaged in any transactions in the Common Stock in the past 60 days.
    (d) Not applicable.
    (e) As described in Item 4, as of October 10, 2024, Boxer Management, Braslyn and Mr. Lewis ceased to beneficially own more than 5% of the outstanding shares of Common Stock.
    Item 7.
    Material to be Filed as Exhibits.

    Item 7 is hereby amended by the addition of the following:

    Exhibit No.
    Description
    Exhibit 3
     
     
    Joint Filing Agreement, dated October 15, 2024, among Boxer Management, Braslyn and Mr. Lewis.






    SIGNATURES
    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.
    Dated:  October 15, 2024
     
       
     
     
     
     
    BOXER ASSET MANAGEMENT INC.
     
     
     
     
     
    By:
    /s/ Paul Higgs
     
        Name:
    Paul Higgs
     
        Title:
    Director
     
     
    BRASLYN LTD.
     
     
     
     
     
    By:
    /s/ Paul Higgs
     
        Name:
    Paul Higgs
     
        Title:
    Director
     
     
    JOSEPH C. LEWIS
     
     
     
     
     
    /s/ Joseph C. Lewis  
      
    Joseph C. Lewis, Individually
     
         




    JOINT FILING AGREEMENT
    PURSUANT TO RULE 13d-1(k)
     In accordance with Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, as amended, the persons named below agree to the joint filing on behalf of each of them of a Statement on Schedule 13D and any amendments to it with respect to Common Stock, $0.001 par value per share, of Tango Therapeutics, Inc. and further agree that this Joint Filing Agreement be included as an Exhibit to those joint filings. Each of the undersigned agrees to be responsible for the timely filing of the Schedule 13D and any amendments thereto, and for the completeness and accuracy of the information concerning itself contained therein. This agreement may be executed in any number of counterparts, all of which taken together shall constitute one and the same instrument.
    Dated: October 15, 2024.
     
       
     
     
     
     
    BOXER ASSET MANAGEMENT INC.
     
     
     
     
     
    By:
    /s/ Paul Higgs
     
        Name:
    Paul Higgs
     
        Title:
    Director
     
     
     
    BRASLYN LTD.
     
     
     
     
     
    By:
    /s/ Paul Higgs
     
        Name:
    Paul Higgs
     
        Title:
    Director
     
     
     
    JOSEPH C. LEWIS
     
     
     
     
     
    /s/ Joseph C. Lewis  
      
    Joseph C. Lewis, Individually
     
         

     






    SCHEDULE A
    ADDITIONAL INFORMATION CONCERNING THE REPORTING PERSONS
    BOXER ASSET MANAGEMENT INC.
    The executive officers and directors of Boxer Asset Management Inc. are set forth below. Each individual’s business address is Albany Financial Center, Suite 207, Lewis Drive, N7776, New Providence, Bahamas. Except as otherwise stated, the present principal occupation or employment set forth below opposite the name of each person refers to employment with Boxer Asset Management Inc.
     
             
    Name
     
    Present Principal Occupation or Employment
     
    Citizenship
    Joe Lewis
     
    Director, President
     
    United Kingdom
    Paul Higgs
     
    Director, Vice President
     
    United States
    BRASLYN LTD.
    The executive officers and directors of Braslyn Ltd. are set forth below. Except as otherwise stated, the present principal occupation or employment set forth below opposite the name of each person refers to employment with Braslyn.


    Name
     
    Position
     
    Present Principal Occupation
    or Employment
     
    Address
     
    Citizenship
    Joe Lewis
     
    Director, President
     
    Private Investor
     
    Albany Financial Center, Suite 207, Lewis Drive, N7776, New Providence, Bahamas
     
    United Kingdom
             
    Paul Higgs
     
    Director, Vice President, Secretary
     
    Accountant
     
    Albany Financial Center, Suite 207, Lewis Drive, N7776, New Providence, Bahamas
     
    Bahamas
             





    SCHEDULE B


    On January 24, 2024, Mr. Lewis pled guilty before the Hon. Jessica G.L. Clarke, in the United States District Court for the Southern District of New York, to one count of conspiracy to commit securities fraud and two counts of securities fraud, in violation of 18 U.S.C. § 371, 15 U.S.C. § 78(b) and 78ff. On April 4, 2024, Judge Clarke sentenced Mr. Lewis to three years of probation, a fine of $5 million and a special assessment of $300.

    Separately, on April 3, 2024, Mr. Lewis reached an agreement with the U.S. Securities and Exchange Commission to settle a civil lawsuit brought against him by the Commission in the United States District Court for the Southern District of New York alleging insider trading violations of the federal securities laws. Mr. Lewis agreed to pay a civil penalty of $1,636,645.11 and agreed to be permanently enjoined by the District Court from violating Section 10(b) of the Securities and Exchange Act of 1934 and Rule 10b-5 promulgated thereunder.







    Get the next $TNGX alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $TNGX

    DatePrice TargetRatingAnalyst
    7/17/2024$19.00Buy
    Jefferies
    4/4/2024Overweight
    Cantor Fitzgerald
    2/12/2024$18.00Overweight
    Piper Sandler
    12/8/2023$16.00Buy
    B. Riley Securities
    10/20/2022$10.00Neutral → Buy
    H.C. Wainwright
    9/20/2021$25.00Outperform
    SVB Leerink
    9/7/2021$12.00Outperform
    Wedbush
    9/7/2021$20.00Outperform
    Wedbush
    More analyst ratings

    $TNGX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by Tango Therapeutics Inc.

      SC 13G - Tango Therapeutics, Inc. (0001819133) (Subject)

      11/20/24 4:24:26 PM ET
      $TNGX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13D/A filed by Tango Therapeutics Inc.

      SC 13D/A - Tango Therapeutics, Inc. (0001819133) (Subject)

      11/7/24 9:35:56 PM ET
      $TNGX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13D/A filed by Tango Therapeutics Inc.

      SC 13D/A - Tango Therapeutics, Inc. (0001819133) (Subject)

      10/28/24 9:22:40 AM ET
      $TNGX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $TNGX
    Leadership Updates

    Live Leadership Updates

    See more
    • Tango Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Highlights

      – Dose escalation ongoing in phase 1/2 trials of lead PRMT5 inhibitors TNG908 and TNG462; additional TNG908 clinical data expected 2024 – – Dose escalation ongoing in phase 1/2 trial of CoREST inhibitor TNG260 and pembrolizumab in patients with STK11 mutant solid tumors – – FDA Fast Track designation granted for TNG348, a novel USP1 inhibitor, for the treatment of BRCA1/2-mutant breast and ovarian cancer; phase 1/2 clinical trial initiation expected 1H 2024 – – Kanishka Pothula, partner at Nextech Ventures, appointed to Board of Directors, replacing Reid Huber, Ph.D., partner at Third Rock Ventures – – Strong cash position of $360 million; cash runway into 2026 expected to fund all clini

      11/8/23 7:00:00 AM ET
      $TNGX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Medicenna Announces the Appointment of Jeff Caravella as Chief Financial Officer

      Jeff Caravella brings over two decades of healthcare expertise steering strategic, financial and operational functions at leading public life-science corporations Mr. Caravella's appointment demonstrates Medicenna's continuing commitment to establish its presence in Boston, the leading biotechnology ecosystem TORONTO and HOUSTON, Aug. 28, 2023 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. ("Medicenna" or the "Company") (NASDAQ:MDNA, TSX:MDNA), a clinical-stage immunotherapy company, today announced the appointment of Jeff Caravella as Chief Financial Officer (CFO). In this position, Mr. Caravella will lead Medicenna's financial strategy to support the Company's growth. This appointmen

      8/28/23 7:00:57 AM ET
      $EDIT
      $MDNA
      $TNGX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Biotechnology: Pharmaceutical Preparations
    • Tango Therapeutics Reports First Quarter 2023 Financial Results and Provides Business Highlights

      – Dose escalation update from ongoing TNG908 clinical trial confirms proof-of-mechanism for MTA-cooperative tumor-selective PRMT5 inhibition in MTAP-deleted cancers – – FDA clears IND application for TNG260, a first-in-class CoREST complex inhibitor for the treatment of STK11-mutant cancers – – Fast Track designation granted by FDA for TNG260 + anti-PD-1 antibody for the treatment of patients with advanced NSCLC with STK11-loss of function mutations – – Strong cash position of $334 million expected to support advancing precision oncology pipeline into 2026 – BOSTON, May 09, 2023 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ:TNGX), a clinical-stage biotechnology company committed

      5/9/23 7:00:00 AM ET
      $TNGX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $TNGX
    SEC Filings

    See more
    • SEC Form S-3 filed by Tango Therapeutics Inc.

      S-3 - Tango Therapeutics, Inc. (0001819133) (Filer)

      5/12/25 5:25:01 PM ET
      $TNGX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 10-Q filed by Tango Therapeutics Inc.

      10-Q - Tango Therapeutics, Inc. (0001819133) (Filer)

      5/12/25 7:10:32 AM ET
      $TNGX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Tango Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - Tango Therapeutics, Inc. (0001819133) (Filer)

      5/12/25 7:06:40 AM ET
      $TNGX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $TNGX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Jefferies initiated coverage on Tango Therapeutics with a new price target

      Jefferies initiated coverage of Tango Therapeutics with a rating of Buy and set a new price target of $19.00

      7/17/24 8:01:05 AM ET
      $TNGX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Cantor Fitzgerald initiated coverage on Tango Therapeutics

      Cantor Fitzgerald initiated coverage of Tango Therapeutics with a rating of Overweight

      4/4/24 8:18:34 AM ET
      $TNGX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Piper Sandler initiated coverage on Tango Therapeutics with a new price target

      Piper Sandler initiated coverage of Tango Therapeutics with a rating of Overweight and set a new price target of $18.00

      2/12/24 6:28:21 AM ET
      $TNGX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $TNGX
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Tango Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Highlights

      – Data update from ongoing TNG462 Phase 1/2 monotherapy trial expected 2H 2025 – – Combination trial of TNG462 + Revolution Medicines RAS(ON) inhibitors on track for enrollment 2Q 2025 – – Cash position of $217 million as of March 31, 2025; cash runway extended into 1Q 2027 with reduction of preclinical spend –   BOSTON, May 12, 2025 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ:TNGX), a clinical-stage biotechnology company committed to discovering and delivering the next generation of precision cancer medicines, reported its financial results for the first quarter ended March 31, 2025, and provided business highlights. "Accumulating data continue to support TNG462 as the potent

      5/12/25 7:00:00 AM ET
      $TNGX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Tango Therapeutics to Report First Quarter 2025 Financial Results on Monday, May 12, 2025

      BOSTON, May 01, 2025 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ:TNGX), today announced that it will report first quarter 2025 financial results on May 12, 2025, before the open of the U.S. financial markets. The company does not intend to hold a conference call. About Tango Therapeutics Tango Therapeutics is a clinical-stage biotechnology company dedicated to discovering novel drug targets and delivering the next generation of precision medicine for the treatment of cancer. Using an approach that starts and ends with patients, Tango leverages the genetic principle of synthetic lethality to discover and develop therapies that take aim at critical targets in cancer. For more info

      5/1/25 7:00:00 AM ET
      $TNGX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Barbara Weber, M.D., Elected to ITM Supervisory Board

      Garching / Munich, Germany, April 09, 2025 – ITM Isotope Technologies Munich SE (ITM), a leading radiopharmaceutical biotech company, today announced the election of Barbara Weber, M.D., to its Supervisory Board, effective May 01, 2025. The election occurred at ITM's Extraordinary General Meeting. Dr. Weber is the President, Chief Executive Officer and Founder of Tango Therapeutics (NASDAQ:TNGX). She has over 25 years of executive and research and development leadership experience in biotech, venture capital and at major pharmaceutical companies, including Novartis (NYSE:NVS) and GlaxoSmithKline (NYSE:GSK). ITM's Supervisory Board and the company overall will benefit from Dr. Weber's deep ex

      4/9/25 5:00:00 AM ET
      $BNTX
      $GSK
      $NVS
      $RLAY
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Biotechnology: Pharmaceutical Preparations

    $TNGX
    Financials

    Live finance-specific insights

    See more

    $TNGX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more

    $TNGX
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Tango Therapeutics to Report First Quarter 2025 Financial Results on Monday, May 12, 2025

      BOSTON, May 01, 2025 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ:TNGX), today announced that it will report first quarter 2025 financial results on May 12, 2025, before the open of the U.S. financial markets. The company does not intend to hold a conference call. About Tango Therapeutics Tango Therapeutics is a clinical-stage biotechnology company dedicated to discovering novel drug targets and delivering the next generation of precision medicine for the treatment of cancer. Using an approach that starts and ends with patients, Tango leverages the genetic principle of synthetic lethality to discover and develop therapies that take aim at critical targets in cancer. For more info

      5/1/25 7:00:00 AM ET
      $TNGX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • General Counsel Barry Douglas sold $16,369 worth of shares (5,330 units at $3.07), decreasing direct ownership by 7% to 66,014 units (SEC Form 4)

      4 - Tango Therapeutics, Inc. (0001819133) (Issuer)

      2/6/25 8:21:04 PM ET
      $TNGX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Chief Financial Officer Beckman Daniella sold $25,282 worth of shares (8,232 units at $3.07), decreasing direct ownership by 5% to 150,284 units (SEC Form 4)

      4 - Tango Therapeutics, Inc. (0001819133) (Issuer)

      2/6/25 8:10:55 PM ET
      $TNGX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Officer Crystal Adam sold $43,866 worth of shares (14,283 units at $3.07), decreasing direct ownership by 8% to 158,210 units (SEC Form 4)

      4 - Tango Therapeutics, Inc. (0001819133) (Issuer)

      2/6/25 8:08:43 PM ET
      $TNGX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Rothenberg Mace bought $74,000 worth of shares (20,000 units at $3.70), increasing direct ownership by 178% to 31,250 units (SEC Form 4)

      4 - Tango Therapeutics, Inc. (0001819133) (Issuer)

      11/18/24 7:20:03 PM ET
      $TNGX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Boxer Capital, Llc bought $8,722,500 worth of shares (1,250,000 units at $6.98) (SEC Form 4) (Amendment)

      4/A - Tango Therapeutics, Inc. (0001819133) (Issuer)

      10/17/23 7:41:18 PM ET
      $TNGX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Boxer Capital, Llc bought $8,722,500 worth of shares (1,250,000 units at $6.98) (SEC Form 4)

      4 - Tango Therapeutics, Inc. (0001819133) (Issuer)

      10/17/23 6:04:34 PM ET
      $TNGX
      Biotechnology: Pharmaceutical Preparations
      Health Care